
Ascendis Pharma (ASND) Stock Forecast & Price Target
Ascendis Pharma (ASND) Analyst Ratings
Bulls say
Ascendis Pharma is supported by a diversified TransCon pipeline with three marketed products that are already showing strong commercial traction, as Q3 revenue of €370M was in line overall while Yorvipath reached €291M, Yuviwel doubled sequentially to €16M, and Skytrofa rose to €59M. The company’s outlook is strengthened by management’s reiterated ≥€5B revenue ambition in 2030 and ≥€10B in 2035, supported by continued U.S. and ex-U.S. expansion, label extensions across age groups and indications, and new combination studies that broaden the addressable market. Fundamentally, the business is also becoming more profitable, with operating cash flow guided to at least €600M in 2026, healthy margins, and buybacks reinforcing the case for accelerating EPS and free cash flow growth.
Bears say
Ascendis Pharma is viewed cautiously because negative readouts from the ongoing later-stage trials for TransCon PTH and TransCon CNP could undermine both regulatory confidence and commercial potential, while any platform-wide safety signal could damage the entire TransCon pipeline. The company has just reached operating profitability, but that milestone may prove fragile if Skytrofa faces intense competition in the large growth hormone market or if Yorvipath adoption is weaker than expected, leading to lower sales and renewed financing needs. Additional downside stems from execution risk, regulatory uncertainty, intellectual property challenges, and long-term pricing pressure, with the downside scenario implying unsuccessful expansion of Skytrofa and TransCon CNP would also erode platform value.
This aggregate rating is based on analysts' research of Ascendis Pharma and is not a guaranteed prediction by Public.com or investment advice.
Ascendis Pharma (ASND) Analyst Forecast & Price Prediction
Start investing in Ascendis Pharma (ASND)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Ascendis Pharma (ASND) Forecast
Ascendis Pharma (ASND) Analyst Forecast & Price Prediction
Start investing in Ascendis Pharma (ASND)
Order type
Buy in
Order amount
Est. shares
0 shares